The concurrent use of aromatase inhibitors and radiotherapy induces echocardiographic changes in patients with breast cancer

Anticancer Res. 2015 Mar;35(3):1559-66.

Abstract

Aim: Adjuvant radiotherapy (RT) for left-sided breast cancer has a negative impact on cardiac health. The concurrent use of aromatase inhibitors (AIs) during RT was found to increase the anticancer efficacy of radiation in pre-clinical models. We evaluated whether the acute effects of RT on cardiac functions are augmented by the concurrent use of AIs.

Patients and methods: Sixty patients with early-stage left-sided breast cancer underwent a 2D echocardiography, electrocardiogram and cardiac biomarker measurements before and after adjuvant breast RT. Data were analyzed in two groups according to AI use.

Results: We observed a significant (p<0.05) decrease in right ventricular systolic function during RT in tricuspid annular plane systolic excursion (TAPSE). TAPSE decreased by 3.0 mm [95% confidence interval (CI)=1.9-4.1 mm] in the AI group and 1.4 mm (95% CI=0.3-2.4 mm) in the non-AI group. In addition, left ventricular diastolic function decreased among patients using AI, as the mitral inflow E-wave decreased 5.8 cm/s (95% CI=1.8-9.7 cm/s) (p=0.006).

Conclusion: The concurrent use of AI during RT for left-sided breast cancer led to a more pronounced change on right ventricular systolic function and left ventricular diastolic functions compared to RT alone.

Keywords: Breast cancer; aromatase inhinitors; cardiotoxicity; radiotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aromatase Inhibitors / therapeutic use*
  • Breast Neoplasms / diagnostic imaging
  • Breast Neoplasms / physiopathology
  • Breast Neoplasms / therapy*
  • Chemoradiotherapy*
  • Echocardiography*
  • Electrocardiography
  • Estradiol / blood
  • Estrogen Receptor beta / physiology
  • Female
  • Heart / radiation effects
  • Humans
  • Middle Aged
  • Prospective Studies
  • Radiotherapy Dosage
  • Ventricular Function, Left

Substances

  • Aromatase Inhibitors
  • Estrogen Receptor beta
  • Estradiol